Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
238
Total raised
£3.1B
disclosed amounts
This month
£7.8M
raised so far
The financing round will help the medical technology company advance its epilepsy diagnosis software towards US and Middle Eastern markets.
"We are delighted to have invested in Neuronostics, whose software as a medical device could revolutionise how neurological conditions are diagnosed and treated."
The funding will support the Edinburgh biotechnology firm in bringing its FDA-approved medical device to international markets.
"Early diagnosis and treatment of tooth decay is essential, allowing patients to reverse the damage to their teeth before it is too late. This investment will enable us to launch our innovative product to global markets – first in the US and eventually in the UK – leading to faster diagnoses and early intervention treatments."
The seed round was led by Eos Advisory with US investor backing to support regulatory approval across international markets.
The medtech firm has raised £2.1m from investors including id4 ventures and Brandenburg Kapital to support its ultrasound software.
"We are thrilled to announce this significant funding milestone and the achievement of key regulatory milestones for our ThinkSono Guidance system. This funding will enable us to further advance our mission of revolutionizing medical imaging technology while our partnerships with NYU Langone Health and Temple Health underscore our commitment to delivering innovative solutions that ultimately improve patient outcomes."
The equity round was led by EQT Life Sciences and Sectoral to support international expansion and clinical trials.
"Dysphagia is a severe medical condition that affects countless patients in hospital. It can increase hospital length of stay, the risk of complications, and lengthens recovery time. The Phagenyx System demonstrates significant reductions in hospital length of stay, with a corresponding and substantial reduction in healthcare costs, as evidenced by the Company’s strong portfolio of high-quality clinical studies. This is strongly aligned with EQT’s Health Economics strategy of transforming cutting-edge scientific innovation into impactful and cost-effective healthcare solutions. We‘re excited to support the next phase of Phagenesis’ journey."
